Anaplastic Multiple Myeloma: An Aggressive Myeloma Variant with A Poor Response to Autologous Stem Cell Transplantation

Year 2024, Volume: 77 Issue: 4, 416 - 418, 31.12.2024

Derya Koyun , İbrahim Öner Doğan Işınsu Kuzu Selami Koçak Toprak , Muhit Özcan , Taner Demirer

https://izlik.org/JA82MY86XG

Abstract

Anaplastic multiple myeloma is an aggressive, chemotherapy-resistant subtype of myeloma with a poor prognosis. Approximately 2% of plasma cell myelomas are pleomorphic, anaplastic, and resemble metastatic tumor cells. Morphological differentiation of anaplastic cells is difficult, and immunohistochemistry and flow cytometry should be performed for immunophenotyping. We shared our experience with peripheral stem cell transplantation in this rare malignancy

Keywords

Anaplastic multiple myeloma , CD38 , Autologous stem cell transplantation

Ethical Statement

The Ankara University Human Research Ethics Committee approved this article (date: 10.12.2021, approval no.: İ11-690-21).

Supporting Institution

-

Project Number

-

Thanks

-

Anaplastik Multiple Miyeloma: Otolog Kök Hücre Nakli Tedavisine Yanıtsız Agresif Miyeloma Varyantı

https://izlik.org/JA82MY86XG

Abstract

Anaplastik multipl miyeloma agresif seyirli, kemoterapilere dirençli, kötü prognozlu miyeloma alt tipidir. Plazma hücreli miyelomun yaklaşık %2’si pleomorfik, anaplastik özellikte olup metastatik tümör hücrelerine benzer. Anaplastik hücrelerin morfolojik ayırımı güç olup, immünfenotipleme için immünhistokimya ve akım sitometrik inceleme yapılmalıdır. Nadir görülen bu malignitede otolog periferik kök hücre nakil deneyimimizi paylaştık.

Keywords

Anaplastik multipl miyeloma , CD38 , Otolog kök hücre nakli

Ethical Statement

-

Supporting Institution

-

Project Number

-

Thanks

-

References

• 1. Ichikawa S, Fukuhara N, Hatta S, et al. Anaplastic multiple myeloma: possible limitations of conventional chemotherapy for long-term remission. J Clin Exp Hematop. 2018;58:39-42.
• 2. Sethi S, Miller. Plasma cell myeloma with anaplastic transformation. Blood. 2016;128:2106.
• 3. Huang JX1, Meng FJ, Feng XQ, et al. Clinical and histopathological analyses of anaplastic myeloma. Chinese Medical Journal. 2020;133:1614-16.
• 4. Singh N, Agrawal N, Mehta A, Panaych A, Sekhri R: CD38-negative myeloma with anaplastic morphology at presentation: a case report. Indian J Hematol Blood Transfus. 2018;34:362-4.
• 5. Aljabry MS: CD38 negative anaplastic plasma cell myeloma with (14; 16) translocation: a diagnostic dilemma for highly aggressive neoplasm: case report. J Hematop. 2019;12:27-30.
• 6. Thi Vinh Do A, Lan Anh L. CD38 - Negative anaplastic plasma cell myeloma: A rare case report. Cureus. 2022;14:e20909.
• 7. Ammannagari N, Celotto K, Neppalli V, Lee K, Holstein SA. Anaplastic Multiple Myeloma: An Aggressive Variant With a Poor Response to Novel Therapies. Clinical Lymphom Myelom Leuk. 2016;16:e129-e131.
• 8. Saburi M, Ogata M, Soga Y, Kondo Y, Kurimoto R, Itani K, Kohno K, Uchida H, Nakayama T. Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma. J Clin Exp Hematop. 2020;60:17- 20.
• 9. Agrawal M, Kanakry J, Arnold CA, Suzman DL, Mathieu L, Kasamon YL, Gladstone DE Ambinder RF, Ghosh N. Sustained remission and reversal of end-organ dysfunction in a patient with anaplastic myeloma. Ann Hematol. 2014;93:1245-1246.
• 10. Tang W, Xu Y, Xiang B. Successful outcome of anaplastic multiple myeloma with lenalidomide, cyclophosphamide, and dexamethasone therapy. Ann Hematol. 2021;100:3039-40.
• 11. Elsabah H, Soliman DS, Ibrahim F, Al-Sabbagh A, Yassin M, Moustafa A, et al. Plasma cell myeloma with an aggressive clinical course and anaplastic morphology in a 22-year-old patient: a case report and review of literature. Am J Case Rep. 2020;21:e920489-1-8.